10 Best Multibagger Stocks To Buy Heading into 2025

8. Capricor Therapeutics, Inc. (NASDAQ:CAPR)

1-Year Share Price Performance: ~515%

2-Year Share Price Performance: ~285%

Average Price Target Upside: 110.59%

Capricor Therapeutics, Inc. (NASDAQ:CAPR)  is a biotechnology company focused on developing cell and exosome-based therapies for muscular diseases. Its leading candidate, deramiocel, is an allogeneic cell therapy currently in Phase 3 trials for Duchenne muscular dystrophy (DMD).

Deramiocel uses cells from healthy human heart tissue to repair damaged muscle and improve heart function, with potential benefits in both cardiac and skeletal muscles. Early studies suggest it can slow muscle degeneration and improve cardiovascular health.

The company is also advancing its StealthX exosome platform in preclinical stages, which aims to deliver oligonucleotides, proteins, and small molecules for several diseases, with a focus on vaccinology and targeted treatments.

In Q3, Capricor (NASDAQ:CAPR) reported a cash position of $85.0 million as of September 30, 2024, up from $39.5 million at the end of 2023. The company raised $52.2 million in net proceeds through an at-the-market offering and an additional $80.8 million from a public offering in October 2024.

However, the company experienced a decline in revenues, which were $2.3 million for Q3 2024, down from $6.2 million in Q3 2023. Operating expenses for Q3 2024 totaled $15.3 million, resulting in a net loss of $12.6 million. The company projects its current financial resources will sustain operations through 2027, excluding additional milestone payments or strategic capital use.

Capricor (NASDAQ:CAPR) is also preparing for the expansion of its manufacturing capacity and has secured a binding term sheet with Nippon Shinyaku for the European commercialization of deramiocel. This agreement includes a $20 million upfront payment, potential milestone payments of up to $715 million, and a double-digit percentage of product revenue.

On November 14, The Fly reported that Cantor Fitzgerald raised its price target for Capricor (NASDAQ:CAPR) to $30 from $25, maintaining an Overweight rating on the stock. The firm noted that the company’s third-quarter earnings report did not reveal any major surprises, but it provided additional insights into its regulatory and commercial plans.

Moreover, the company has attracted significant interest from new investors, many of whom were impressed by the high royalty expectations from its partnership. Cantor Fitzgerald believes the company could achieve annual peak revenues of approximately $1 billion in the U.S. alone.